Abstract:While small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC) are distinct classes of high-grade neuroendocrine carcinomas, the differential diagnosis between SCLC and LCNEC remains challenging. In fact SCLC and LCNEC overlap in clinical, histopathologic, cytologic, morphologic and genetic characteristics. Molecular profiling with microarray or next-generation sequencing has provided growing evidence suggesting that both SCLC and LCNEC are biologically heterogeneous and a great part of them are borderline neuroendocrine carcinomas falling between typical SCLC and LCNEC. On account of accumulated knowledge, we speculated that immunogenomically characterizing SCLC and LCNEC collectively as one group, or rather morphologically or cytologically separating SCLC from LCNEC has superior clinical value. We analyzed gene expression profiles of 44 SCLCs, 56 LCNECs and 25 normal lung samples obtained from Gene Expression Omnibus. Unsupervised and supervised analyses were performed to understand molecular characteristics of samples. Pathway and CIBERSORT analyses were employed to obtain immune landscape of SCLC and LCNEC. Unsupervised clustering with 1189 differentially expressed genes revealed 2 distinct molecular subgroups (G1 and G2) of SCLC and LCNEC, which is not associated with histopathology. Targeted pathway analysis found that G1 was marked by activated IL-17, MAPK and Hippo signaling pathways. In contrast, transcriptional factors, such as ASCL1, INSM1, SOX2, and NKX2-1 were significantly up-regulated in G2, but not in G1. Moreover, in silico analysis of cellular composition and expression of immune genes disclosed unique immunoprofiles for G1 and G2. G1 was characterized by enriched CD4 memory cells, M1 macrophages and activated dendritic cells. While G2 was composed of high fractions of memory B cells and naïve CD4 cells. Strikingly, expression of both immunoinhibitors (IL10, PDL1, IDO1) and immunomodulators (OX40L, BAFF, GITR, IL6), as well as MHC class I and II molecules was higher in G1 compared to that in G2. We identified the common intrinsic features and molecular subgroups of SCLC and LCNEC, which are beyond conventional histopathology and better associated with immunogenomics of tumors. Further research is warranted to identify potential clinical implication of SCLC and LCNEC molecular subgroups.

Molecular pathology of small cell lung cancer: Overview from studies on neuroendocrine differentiation regulated by ASCL1 and Notch signaling

Molecular features and evolutionary trajectory of ASCL1 + and NEUROD1 + SCLC cells

Genomic and Gene Expression Studies Helped to Define the Heterogeneity of Small-Cell Lung Cancer and Other Lung Neuroendocrine Tumors and to Identify New Therapeutic Targets

Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer

ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer

Advances in novel molecular typing and precise treatment strategies for small cell lung cancer

Relationship Between Neuroendocrine and Immune Gene Expression in Small Cell Lung Cancer

[Regulation and Mechanism of Notch Signaling Pathway in Small Cell Lung Cancer].

ASCL1, NKX2-1, and PROX1 co-regulate subtype-specific genes in small-cell lung cancer

Neuroendocrine Subtypes of Small Cell Lung Cancer Differ in Terms of Immune Microenvironment and Checkpoint Molecule Distribution.

Differential development of large-cell neuroendocrine or small-cell lung carcinoma upon inactivation of 4 tumor suppressor genes

Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts

The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells

Cnsc-61. Neuronal-Activity Dependent Mechanisms Of Small Cell Lung Cancer Pathogenesis

Small-cell lung cancer neuronal features and their implications for tumor progression, metastasis, and therapy

Comparative Expression Analysis in Small Cell Lung Carcinoma Reveals Neuroendocrine Pattern Change in Primary Tumor Versus Lymph Node Metastases.

Epigenetic Regulators Open the Door to SCLC Plasticity

ASCL1 restrains ERK1/2 to promote survival of a subset of neuroendocrine lung cancers

P3.12-10 Immunogenomic Characteristics of SCLC and LCNEC Redefined Molecular Subgroups

Transcriptional Circuitry of NKX2-1 and SOX1 Defines an Unrecognized Lineage Subtype of Small-Cell Lung Cancer